Arcturus Therapeutics (ARCT) is continuing to evaluate the use of LUNAR-CF [ARCT-032] for the treatment of patients with Cystic Fibrosis [CF]. Read our latest report on the stock here.

Recent periods of financial stress and the proliferation of risks across the financial system are fueling the development of ...

Unusually dry weather, an abundance of ‘dry fuels’, low relative humidity and strong winds combine to create high risk of ...

Research shows frailty levels rise significantly before dementia, suggesting it could be a key marker for early ...

The association between gestational organophosphate ester (OPE) exposure and obesity in childhood is mixed, according ...

The weather on Tuesday will make it much tougher for the crews continuing to battle the Jennings Creek Wildfire, which is ...

Global investors are likely to find relative safety in India’s financial markets from the spillover of Donald Trump’s economic policies, including from any protectionist trade policies that could ...

The value of Harvard’s endowment grew in value in fiscal year 2024 for the first time in three years. But financial experts ...

Cardano jumps 76% amid renewed whale interest, reaching new highs. Key supports at $0.54 and $0.46 could stabilize ADA if selling occurs.

October 2024 was record to near-record dry for a large portion of the Eastern US, including several major cities. This has ...

Being started on a smaller dose of the approved early Alzheimer’s therapy Kisunla was found to reduce the risk of ARIA-E on imaging scans.

Following a scientific review, the Food and Drug Administration (FDA) has issued a renewal of modified risk granted orders to ...